Stifel Financial’s Fulgent Genetics FLGT Stock Holding History

Stifel Financial’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,513	Closed	-$533K	–	3332
2021 Q1	$533K	Buy	+5,513	New	+$569K	﹤0.01%	2450

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Stifel Financial's FLGT Position: Q2 2021 in Review

Stifel Financial sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 5,513 shares — an estimated $533K sold.

Stifel Financial first reported a position in FLGT in Q1 2021 and held it in 1 quarter. The position peaked at $533K in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

Stifel Financial reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
Stifel Financial sold 5,513 Fulgent Genetics shares in Q2 2021, an estimated $533K.
Stifel Financial first reported a position in Fulgent Genetics in Q1 2021 and held it in 1 quarter.
Stifel Financial's Fulgent Genetics position peaked at $533K in Q1 2021.
254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Stifel Financial's 13F filing for Q2 2021, filed 13 Aug 2021.